apoptotic cells. The 7-AAD-positive cells showed the characteristic upmodulation of CD20 and downmodulation of CD10, comparable to the immunophenotypic modulation observed in vivo. In contrast, the viable 7-AAD-negative cells retained their original immunophenotype (Figure 2e , f). For each antibody, the MFI differed between the viable and dead cells, but within these two populations the MFI was not affected by the type and dose of the cytotoxic agents to which the cells were exposed (data not shown). Further analysis of dead and viable cells showed that dead cells had a higher MFI for each isotype control antibody than viable cells. This increase in background staining was comparable to the upmodulation of CD20 on CD20-negative leukemic cells observed in day 15 and 28 samples. Altogether, these data indicate that the immunophenotypic modulation observed in vitro is due to the induction of cell kill, resulting in a higher aspecific staining and a decreased expression of membrane antigens.
Our data suggest that in ALL patients undergoing treatment, immunophenotypic modulation is caused by drug-induced cell death, resulting in loss of membrane antigens and higher aspecific staining. Our data are in agreement with a recent study, which showed that the loss of expression of lineage antigens (such as CD19) is a common feature of lymphocytes undergoing apoptosis and that the MFI for different antigens might drop to undetectable levels during different stages of apoptosis. 5 Antigens coexpressed on the same cells showed different degrees of loss in the different stages of apoptosis, suggesting that it is a specific, active process, rather than a general degradation of cell components. 5 Our observation that immunophenotypic modulation is due to apoptotic cells also explains why ALL blast cells in resistant patients show no modulation. 1 In conclusion, our data indicate that immunophenotypic modulation in ALL patients undergoing treatment can (at least in part) be explained by the induction of cell death. Characterization of the molecular lesion(s) underlying the Philadelphia-negative chronic myeloproliferative disorders (MPD), including polycythemia vera (PV), essential thrombocythemia (ET), and chronic idiopathic myelofibrosis (IM), has represented a formidable task since their description. 1 However, four independent groups recently detected an acquired mutation in exon 12 of the JAK2 gene, causing a phenyalanine-valine substitution at position 617 (V617F) in the negative autoregulatory JH2 pseudokinase domain. The mutation was detected in 81% (range, 65-97%) of patients with PV, 39% (23-57%) with ET, and 43% (35-50%) with IM. [2] [3] [4] [5] The percentage of patients with homozygote JAK2 V617F mutation was around 27% in PV, 18% in IM, and 3% in ET, 2, 4, 5 and was coherent with the loss of heterozygosity at chromosome 9p24, previously reported in E30% of PV subjects. 6 The V617F JAK2 is a constitutively activated tyrosine kinase that confers erythropoietin hypersensitivity and growth-factor independence in transfected cell lines [3] [4] [5] and induces erythrocytosis in a murine transplant model. 3 These findings are consistent with a pathogenetic role of mutated JAK2 in the myeloproliferation typical of MPD; however, how a single mutation may be responsible for such different clinical phenotypes, and whether MPD patients presenting the JAK2 mutation differ from those who actually lack it, is unknown.
We searched for possible associations of the JAK2 V617F mutation with disease phenotype, including clinical characteristics and laboratory parameters such as endogenous erythroid colony formation (EEC), clonality status by means of the X-chromosome inactivation pattern (XCIP), PRV-1 overexpression, or platelet cMpl content, in 130 patients with ET. Diagnosis of ET was made according to the WHO criteria; 7 in all cases, a bone marrow biopsy was available, and in older cases, clinical records and histopathologic findings were carefully reviewed to establish diagnosis. All subjects gave informed consent to be included in the study; their characteristics are reported in Table 1 . At the time of blood sampling for laboratory tests, patients were either untreated or had been therapy-free for at least the past 3 months.
Assay for EEC in the peripheral blood, quantification of PRV-1 gene expression in granulocytes, of Mpl content in platelet extracts, and the analysis of XCIP were performed as previously described. 8 Search for JAK2 mutation was performed by an allele-specific PCR, starting from 75 ng DNA purified from granulocytes. 2 To evaluate whether the mutation was carried in the homozygous or heterozygous state, digestion of PCR products with BsaXI restriction enzyme (New England Biolabs, Hitchin, UK) was performed as described. 2 Assays were conducted blindly and results analyzed at the end of all experiments. Statistical analysis was performed with SPSS software (Statistical Package for the Social Sciences, release 11.5.1) using the w 2 and Fisher's exact test for nominal variables, Mann-Whitney test for continuous variable, and binary logistic regression for multivariate analysis. All tests were two-sided, and a Po0.05 was considered statistically significant.
The overall frequency of JAK2 V617F mutation (57%) observed in our ET patient population was close to the value reported by Baxter et al 2 and slightly higher than that reported by others; 4, 5 homozygosity was found at a 6% rate. There was no difference in age or sex between JAK2 V617F positive or negative patients, although we had an excess of female subjects for trivial reasons. Both disease duration and the proportion of subjects who had required therapy for the control of thrombocytosis were similar in JAK2 mutated and wild-type patients. Only one subject, who showed homozygosity for the V617F mutation, evolved to acute leukemia; therefore, assessment of the role of mutated JAK2 in the evolution of ET to leukemia was not feasible. Patients with JAK2 V617F had higher hematocrit and hemoglobin levels (P ¼ 0.0001 and 0.001, respectively), while platelet count was lower (P ¼ 0.004), than wild-type subjects; the effect of mutated JAK2 on hematocrit level was maintained in multivariate analysis (P ¼ 0.008; 95% confidence limits 1.04-1.35). We carefully reviewed clinical records of these subjects to exclude masked PV, but none of them actually satisfied WHO diagnostic criteria for the latter disease.
In all, 26 patients (20%) suffered from major thrombotic events (30 events), and eight (6%) from major hemorrhages; neither were related to the presence of JAK2 mutation (Table 1) . On the contrary, there was a correlation between major thromboses and XCIP clonality in female patients (P ¼ 0.038), as reported. 8 Patients with JAK2 mutation had a higher frequency of EEC (55 vs 38%) and PRV-1 overexpression (40 vs 33%) and, on the other hand, less frequently reduced c-Mpl platelet content (66 vs 81%), but none of these differences was statistically significant. The percentage of subjects with clonal hemopoiesis was identical in the two groups (66%); the findings of JAK2 mutation in females with a polyclonal pattern of hematopoiesis, based on the XCIP analysis, was not unexpected, since the allele-specific PCR strategy used for the detection of mutated JAK2 alleles has a sensitivity of as few as 3% of nucleated cells, 2 as compared to an at least 75% clonal allele predominance that is required for the definition of clonality with the HUMARA assay. On the other hand, the fact that as many as 43% Table 1 Patient characteristics, and results of laboratory assays, according to the presence or not of JAK2 V617F mutation in granulocytes Disease duration, months from the original diagnosis to the time when blood sampling for this study was performed. Thrombosis refers to major thrombotic events only, which included acute myocardial infarction (two events), cerebrovascular thromboses (nine events), Budd-Chiari syndrome (four events), deep venous thrombosis (10 events), and third-trimester abortion (five events). Hemorrhages were represented by gastrointestinal bleeding (four subjects), severe epistaxis (one subject) and diffuse hematomas including muscle hematomas (three subjects). a The number of patients evaluable for each assay is reported within paranthesis. XCIP analysis was performed on 102 females who were p60 years; of these, 12 were not evaluable because of homozygosity at the HUMARA locus (four subjects) or an ambiguous inactivation pattern (eight subjects).
Correspondence of females showing clonal myelopoiesis on XCIP analysis (26/60) actually had wild-type JAK2 is of particular interest, since it reinforces the view that mutations other than JAK2 V617F are potentially implicated in the pathogenesis of ET (Table 2) . In summary, our data on a large population of subjects with a diagnosis of ET confirm recent observations that around half of them have the JAK2 V617F mutation in granulocytes; however, the presence of the mutation does not appear to correlate with specific clinical-laboratory characteristics, so that, apart from the diagnostic power, its role in the clinical management of patients remains to be ascertained. 
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